Mo Brooks: This Isn’t Hogwarts. Trump Doesn’t Have a Magic Wand to Fix Drug Prices

HHS, CMS Target "Most-Favored-Nation" Drug Pricing To Combat Global "Freeloading"

The U.S. Department of Health and Human Services (HHS) today announced immediate steps to implement President Trump’s “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” Executive Order, a key initiative aimed at significantly lowering healthcare costs for Americans. The Department has identified specific targets for pharmaceutical manufacturers to meet, ensuring Americans no longer pay more […] HHS, CMS Target “Most-…

US health authorities set most-favored-nation pricing targets

WASHINGTON (Reuters) - The U.S. Department of Health and Human Services said on Tuesday it was setting most-favored-nation prescription drug pricing targets following an executive order by President Donald Trump.

Mo Brooks: This isn’t Hogwarts. Trump doesn’t have a magic wand to fix drug prices

Trump’s drug pricing executive order is an example of how not to do things.

HHS, CMS Set Most-Favored-Nation Pricing Targets to End Global Freeloading on American Patients - Oklahoma Farm Report

Most-Favored-Nation policy builds on President Trump’s broader reforms to eliminate global freeloading and ensure every American has access to affordable, life-saving treatments. The U.S. Department of Health and Human Services announced today that it is taking immediate steps to implement President Trump’s Executive Order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” a central component of the Administration…

How Trump's New Drug Pricing EO Differs From Past Attempts: John Barkett, MBA

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power. What Happened: According to…